Yangpu Medical (300030.SZ) issued an announcement. The company's stock trading price was traded for 2 consecutive trading days (2024...
Zhitong Finance App News, Yangpu Healthcare (300030.SZ) issued an announcement. The cumulative deviation value of the company's stock trading price increase exceeded 30% for 2 consecutive trading days (September 9, 2024 and September 10, 2024). According to the relevant regulations of the Shenzhen Stock Exchange, this is a situation where stock trading fluctuates abnormally.
The company is concerned that on September 7, 2024, the Ministry of Commerce, the National Health Commission, and the State Drug Administration issued the “Notice on Launching Pilot Work to Expand Openness in the Medical Field”. From the date of publication of this notice, foreign-invested enterprises are allowed to develop and apply human stem cells, genetic diagnosis and treatment technology in the China (Beijing) Pilot Free Trade Zone, China (Guangdong) Pilot Free Trade Zone, and the Hainan Free Trade Port for product registration, marketing and production. All products that have been registered, marketed and approved for production can be used nationwide.
Currently, the company's shareholding subsidiary Hangzhou Kangdaisirui Biotechnology Co., Ltd. is a foreign-invested enterprise, mainly engaged in R&D, production, sales and technical services of POCT molecular diagnostic instruments and supporting reagent products. The business does not include the development and application of human stem cells and genetic diagnosis and treatment technology.